Concise Review: Patient-Derived Stem Cell Research for Monogenic Disorders

Area of Science:

• Regenerative Medicine
• Genetics
• Molecular Biology

Background:

• Monogenic disorders (MGDs) result from single gene mutations, posing significant health challenges with limited treatment options.
• Patient-derived stem cells are emerging as a powerful tool for understanding MGD molecular mechanisms and discovering new therapeutic targets.
• Current therapeutic strategies for MGDs are largely ineffective, necessitating innovative approaches.

Purpose of the Study:

• To review the latest advancements in using patient-derived stem cells for potential MGD treatments.
• To explore the application of genome editing technologies in correcting MGD-associated mutations.
• To predict future research directions in stem cell-based MGD therapies.

Main Methods:

• Utilizing patient-derived stem cells to model MGDs and investigate disease mechanisms.
• Employing genome editing tools (ZFNs, TALENs, CRISPR/Cas9) to correct MGD-causing mutations in vitro.
• Transplanting gene-corrected stem cells into MGD animal models to evaluate safety and efficacy.

Main Results:

• Demonstrated potential for patient-derived stem cells to elucidate MGD pathogenesis.
• Successful correction of MGD-associated gene mutations in stem cells using advanced genome editing techniques.
• Preliminary assessment of the safety and therapeutic effects of gene-corrected stem cells in preclinical models.

Conclusions:

• Patient-derived stem cells, combined with genome editing, represent a promising avenue for MGD treatment development.
• Further research is crucial to overcome challenges like stem cell tumorigenicity and genetic modification safety for clinical translation.
• Continued basic research will drive the clinical application of patient-specific stem cells in managing monogenic disorders.